These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Human Immunodeficiency Virus Type 1 RNA Levels in Rectal and Seminal Compartments After Switching to Long-Acting Cabotegravir Plus Rilpivirine: A Longitudinal Study. Masiá M; Fernández-González M; Agulló V; Mascarell P; Padilla S; García-Abellán J; Gutiérrez F Clin Infect Dis; 2023 Feb; 76(3):e748-e751. PubMed ID: 35986671 [TBL] [Abstract][Full Text] [Related]
46. HIV drug resistance monitoring in the era of dolutegravir and injectable long-acting cabotegravir in resource-limited settings. Washaya T; Manasa J; Kouamou V AIDS; 2023 Aug; 37(10):1629-1631. PubMed ID: 37450629 [No Abstract] [Full Text] [Related]
47. Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy. Gagliardini R; Gianotti N; Maggiolo F; Cozzi-Lepri A; Antinori A; Nozza S; Lapadula G; De Luca A; Mussini C; Gori A; Saracino A; Andreoni M; Monforte AD; Int J Antimicrob Agents; 2021 Oct; 58(4):106406. PubMed ID: 34293454 [TBL] [Abstract][Full Text] [Related]
48. HIV Treatment and Prevention: An Overview of Recommendations From the IAS-USA Antiretroviral Guidelines Panel. Volberding PA Top Antivir Med; 2017; 25(1):17-24. PubMed ID: 28402930 [TBL] [Abstract][Full Text] [Related]
49. Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the Han K; Gevorkyan H; Sadik Shaik J; Crauwels H; Leemereise C; Bontempo G; Win B; Chounta V; Seal C; DeMoor R; D'Amico R; Spreen WR; Ford SL Antimicrob Agents Chemother; 2024 Jan; 68(1):e0078123. PubMed ID: 38038460 [TBL] [Abstract][Full Text] [Related]
50. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study. Orkin C; Bernal Morell E; Tan DHS; Katner H; Stellbrink HJ; Belonosova E; DeMoor R; Griffith S; Thiagarajah S; Van Solingen-Ristea R; Ford SL; Crauwels H; Patel P; Cutrell A; Smith KY; Vandermeulen K; Birmingham E; St Clair M; Spreen WR; D'Amico R Lancet HIV; 2021 Nov; 8(11):e668-e678. PubMed ID: 34656207 [TBL] [Abstract][Full Text] [Related]
51. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Jaeger H; Overton ET; Richmond G; Rizzardini G; Andrade-Villanueva JF; Mngqibisa R; Hermida AO; Thalme A; Belonosova E; Ajana F; Benn PD; Wang Y; Hudson KJ; Español CM; Ford SL; Crauwels H; Margolis DA; Talarico CL; Smith KY; van Eygen V; Van Solingen-Ristea R; Vanveggel S; Spreen WR Lancet HIV; 2021 Nov; 8(11):e679-e689. PubMed ID: 34648734 [TBL] [Abstract][Full Text] [Related]
52. The optimum implementation of long-acting injectable cabotegravir-rilpivirine in sub-Saharan Africa. Dawood H Lancet Glob Health; 2021 May; 9(5):e563-e564. PubMed ID: 33770512 [No Abstract] [Full Text] [Related]
53. Cabotegravir/rilpivirine (Cabenuva) for HIV-1 infection. Med Lett Drugs Ther; 2021 May; 63(1625):81-83. PubMed ID: 34180282 [No Abstract] [Full Text] [Related]
54. Cabotegravir (Apretude) for Pre-exposure Prophylaxis for HIV Type 1 Infection. El-Haddad A; Erlich D Am Fam Physician; 2023 May; 107(5):545-546. PubMed ID: 37192084 [TBL] [Abstract][Full Text] [Related]
55. Use of long-acting injectable antiretroviral agents for human immunodeficiency Virus: A review. Ariyo OE; Jones CE J Clin Virol; 2022 Jan; 146():105032. PubMed ID: 34883407 [TBL] [Abstract][Full Text] [Related]
56. Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression. Swindells S; Andrade-Villanueva JF; Richmond GJ; Rizzardini G; Baumgarten A; Masiá M; Latiff G; Pokrovsky V; Bredeek F; Smith G; Cahn P; Kim YS; Ford SL; Talarico CL; Patel P; Chounta V; Crauwels H; Parys W; Vanveggel S; Mrus J; Huang J; Harrington CM; Hudson KJ; Margolis DA; Smith KY; Williams PE; Spreen WR N Engl J Med; 2020 Mar; 382(12):1112-1123. PubMed ID: 32130809 [TBL] [Abstract][Full Text] [Related]
57. Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy. Mills A; Richmond GJ; Newman C; Osiyemi O; Cade J; Brinson C; De Vente J; Margolis DA; Sutton KC; Wilches V; Hatch S; Roberts J; McCoig C; Garris C; Vandermeulen K; Spreen WR AIDS; 2022 Feb; 36(2):195-203. PubMed ID: 34652287 [TBL] [Abstract][Full Text] [Related]
58. A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV. Bares SH; Scarsi KK Curr Opin HIV AIDS; 2022 Jan; 17(1):22-31. PubMed ID: 34871188 [TBL] [Abstract][Full Text] [Related]
59. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial. Ramgopal MN; Castagna A; Cazanave C; Diaz-Brito V; Dretler R; Oka S; Osiyemi O; Walmsley S; Sims J; Di Perri G; Sutton K; Sutherland-Phillips D; Berni A; Latham CL; Zhang F; D'Amico R; Pascual Bernáldez M; Van Solingen-Ristea R; Van Eygen V; Patel P; Chounta V; Spreen WR; Garges HP; Smith K; van Wyk J Lancet HIV; 2023 Sep; 10(9):e566-e577. PubMed ID: 37567205 [TBL] [Abstract][Full Text] [Related]
60. Brief communications: changes in inflammatory biomarkers and lipid profiles after switching to long-acting cabotegravir plus rilpivirine. Adachi E; Saito M; Otani A; Koga M; Yotsuyanagi H AIDS Res Ther; 2024 Jan; 21(1):1. PubMed ID: 38173008 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]